感染

订阅

MedSci主页 / 所有栏目 / 感染

Respir Investig：贝达奎林治疗耐多药结核病的效果和安全性

2020-04-09 MedSci原创 MedSci原创

多药耐药结核病贝达喹啉
关注

C209试验中使用贝达奎林治疗的韩国多药耐药结核病（MDR-TB）患者的最终治疗结果尚未报道。因此，我们对C209试验的韩国人群进行了亚组分析，并将结果与C209研究总体人群进行比较。

C209试验中使用贝达奎林治疗的韩国多药耐药结核病（MDR-TB）患者的最终治疗结果尚未报道。因此，我们对C209试验的韩国人群进行了亚组分析，并将结果与C209研究总体人群进行比较。

 

在C209试验中，MDR-TB患者接受了24周的贝达奎林联合抗结核药物治疗，并在贝达奎林治疗开始后随访至第120周。

 

除药物易感性模式外，两组患者的基线临床特征相似。在韩国和C209总体人群中，广泛耐药前结核病与广泛耐药结核病（pre-XDR-TB/XDR-TB）的比例分别为61.9和35.2%。氨基糖苷类药物、晚期氟喹诺酮类药物、环丙沙林和利奈唑仑是贝达奎林治疗过程中最常联合使用的药物。两组患者在第24周（贝达奎林治疗结束；80.0% vs. 79.5%）和120周（75.0% vs. 72.2%）时的培养转化率相似。此外，两组患者治疗期间的不良事件发生频率和类型相似，有1例患者（5.0%）患者发生与贝达奎林治疗无关的死亡。

 

综上所述，该研究结果表明，尽管韩国MDR-TB患者的耐药性较高，但是贝达奎林在这些患者中表现出相似的疗效和安全性，可能是由于与其他药物如利奈唑仑等联用的原因。

 

原始出处：

 

Ji Hyun Kim, O Jung Kwon, et al., Bedaquiline in multidrug-resistant tuberculosis treatment: Safety and efficacy in a Korean subpopulation. Respir Investig. 2020 Jan;58(1):45-51.  

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1254350, encodeId=6baf1254350b9, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sat Apr 11 12:03:35 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458409, encodeId=ac49145840970, content=<a href='/topic/show?id=a39f803557a' target=_blank style='color:#2F92EE;'>#耐多药结核病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80355, encryptionId=a39f803557a, topicName=耐多药结核病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa6e6064686, createdName=mgqwxj, createdTime=Sat Apr 11 12:03:35 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051544, encodeId=9c7e2051544e1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Feb 18 16:03:35 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047032, encodeId=4064104e032e5, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Fri Apr 10 00:03:35 CST 2020, time=2020-04-10, status=1, ipAttribution=)]
    2020-04-11 huhuaidong387

    #结核#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1254350, encodeId=6baf1254350b9, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sat Apr 11 12:03:35 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458409, encodeId=ac49145840970, content=<a href='/topic/show?id=a39f803557a' target=_blank style='color:#2F92EE;'>#耐多药结核病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80355, encryptionId=a39f803557a, topicName=耐多药结核病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa6e6064686, createdName=mgqwxj, createdTime=Sat Apr 11 12:03:35 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051544, encodeId=9c7e2051544e1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Feb 18 16:03:35 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047032, encodeId=4064104e032e5, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Fri Apr 10 00:03:35 CST 2020, time=2020-04-10, status=1, ipAttribution=)]
    2020-04-11 mgqwxj

    #耐多药结核病#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1254350, encodeId=6baf1254350b9, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sat Apr 11 12:03:35 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458409, encodeId=ac49145840970, content=<a href='/topic/show?id=a39f803557a' target=_blank style='color:#2F92EE;'>#耐多药结核病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80355, encryptionId=a39f803557a, topicName=耐多药结核病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa6e6064686, createdName=mgqwxj, createdTime=Sat Apr 11 12:03:35 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051544, encodeId=9c7e2051544e1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Feb 18 16:03:35 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047032, encodeId=4064104e032e5, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Fri Apr 10 00:03:35 CST 2020, time=2020-04-10, status=1, ipAttribution=)]
    2021-02-18 xiangyuzhou971

    #EST#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1254350, encodeId=6baf1254350b9, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sat Apr 11 12:03:35 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458409, encodeId=ac49145840970, content=<a href='/topic/show?id=a39f803557a' target=_blank style='color:#2F92EE;'>#耐多药结核病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80355, encryptionId=a39f803557a, topicName=耐多药结核病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa6e6064686, createdName=mgqwxj, createdTime=Sat Apr 11 12:03:35 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051544, encodeId=9c7e2051544e1, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Feb 18 16:03:35 CST 2021, time=2021-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047032, encodeId=4064104e032e5, content=疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Fri Apr 10 00:03:35 CST 2020, time=2020-04-10, status=1, ipAttribution=)]
    2020-04-10 CHANGE

    疗效只是效果的众多方面之一，还要看对患者的获益，包括生活质量等因素共同决定效果的

    0